KOD

97.1700.75%
JA

John A. Borgeson

Executive VP, CFO & Secretary

Mr. John A. Borgeson, MBA, CPA has been Chief Financial Officer and Secretary at Kodiak Sciences Inc since January 2016. He is an Executive Vice President at Kodiak Sciences Inc and served as its Senior Vice President. Mr. Borgeson served as Chief Financial Officer at Solstice Biologics LLC since June 2014. Mr. Borgeson served as the Acting Chief Financial Officer at Aridis Pharmaceuticals Inc. He was financial advisor to Solstice since its inception. Mr. Borgeson spent many years at Pfizer where he was a member of Pfizer's Financial Leadership Team and held several financial positions of increasing responsibility. He has over many years of pharmaceutical industry experience in finance, strategy and operations on a global scale. At Pfizer, he served as Vice President, Finance, where he had broad strategic, financial and operational responsibility over a start-up division focused on biotherapeutic research and development, where he had broad strategic, financial and operational responsibility over building Pfizer's biotechnology franchise. Since leaving Pfizer in 2010, Mr. Borgeson has helped oversee finance for a variety of private companies, including venBio portfolio companies Labrys Biologics (recently acquired by Teva Pharmaceuticals) and Heart Metabolics Limited. He has also helped oversee finance at venBio. He started his career at Ernst & Young. Mr. Borgeson’s roles at Pfizer included finance head for Pfizer’s biotherapeutics and bioinnovation group and corporate tax executive with responsibility for the United States and Europe. He is a Certified Public Accountant. From January 2013 until December 2015, Mr. Borgeson led finance for a variety of private biotech companies, including ALX Oncology and also including Labrys Biologics, Inc., which was acquired by Teva Pharmaceuticals. He has an MBA from R.I.T. and a BS from the School of Management at the University at Buffalo (S.U.N.Y.).

Positions